Some of the content on this page has been created using generative AI.
What is it about?
The iROC trial compared robot-assisted with open surgery for radical cystectomy in bladder cancer patients. The study showed a benefit for the robot-assisted approach in days alive and out of the hospital in the first 90 days after surgery. However, it is unclear if the results can be generalized to the United States, as patients in the trial may have been healthier and younger than real-world patients. A comparison of patient characteristics from the iROC trial to a real-world US surgical database showed differences in age, obesity, smoking, anemia, preoperative hemoglobin, and creatinine levels, as well as cancer stage and nodal positivity.
Featured Image
Why is it important?
This research is important because it provides a comparison between patient characteristics and outcomes in a landmark surgical trial (iROC trial) and a real-world, multi-institutional surgical database (NSQIP) in the United States. The iROC trial showed a benefit with a robot-assisted approach in bladder cancer surgery, but the generalizability of the trial results to patients in the United States remains unclear. This comparison helps to identify potential differences between trial participants and real-world patients, highlighting the importance of validating the findings of the iROC trial in diverse international populations. Key Takeaways: 1. The iROC trial participants appeared to be younger, healthier, and had lower cancer stage compared to a large, multi-institutional United States cohort in the NSQIP database. 2. These differences in patient characteristics may affect the generalizability and applicability of the iROC trial results to real-world patients in the United States. 3. Further research is needed to understand the most important factors in surgical selection for the robot-assisted and open approach to radical cystectomy with urinary diversion. 4. Validating the findings of the iROC trial in diverse international populations is crucial to ensure the applicability of the trial results to various patient populations.
AI notice
Read the Original
This page is a summary of: Comparison of the ‘iROC’ trial participants to patients with bladder cancer in the United States undergoing radical cystectomy, BJU International, January 2023, Wiley,
DOI: 10.1111/bju.15954.
You can read the full text:
Contributors
Be the first to contribute to this page







